聚乙二醇干扰素治疗慢性丙型肝炎临床观察

目的探讨聚乙二醇干扰素-α(PEG-INF-α)联合利巴韦林(RBV)治疗慢性丙型肝炎的临床疗效及安全性。方法在76例慢性丙型肝炎患者中,37例(A组)接受PEG-INF-α2a治疗48周,39例(B组)接受PEG-INF-α2b治疗48周,两组均联合应用RBV口服。在治疗结束后随访24周。结果 76例患者在疗程结束时,肝功能全部复常,HCV RNA均低于检测下限(<5×102拷贝/毫升)。停药后随访24周,75例患者获得SVR;在PEG-INF-α治疗过程中,A组出现发热2例,肌肉酸痛2例,脱发32例,消瘦27例;B组出现发热30例,肌肉酸痛31例,脱发28例,消瘦33例。结论 PEG-INF-α联合利巴韦林治疗慢性丙型肝炎安全有效,两种药物的效果无明显差异。

Clinical efficacy of pegylated-interferon-α combination with ribavirin in the treatment of patients with ;chronic hepatitis C

Objective To evaluate the efficacy and safety of polyethylene glycol interferon-α（PEG-INF-α） combination with ribavirin in the treatment of patients with chronic hepatitis C（CHC）. Methods 76 patients with CHC were included in this study,and 37 patients （group A） were treated with PEG-INF α-2a,and 39 patients （group B） were treated with PEG-INF α-2b. The regimen lasted 48 weeks,and all patients were followed-up for 24 weeks after treatment. Results The ALT normalization and HCV RNA loss were found in all 76 patients with CHC at the end of the treatment,and the sustained virologic rate was 97.4% in group A,and 98.6% in group B at the end of 24 week follow-up;the side effects were fever in 2,muscular soreness in 2,alopecia in 32 and weight loss in 27 in group A,while they were 30,31,28 and 33 in group B,respectively. Conclusion Polyethy-lene glycol interferon-α plus ribavirin treatment for patients with CHC is safe and effective,and the efficacy of PEG-INFα-2a plus ribavirin is similar to that of PEG-INFα-2b plus ribavirin.